BioVie Inc. (NASDAQ: BIVI) - Company Note
In the past six months, BioVie has gained considerable attention from the market due to NE3107’s promising clinical findings in Alzheimer’s disease (AD) and Parkinson’s disease (PD). These findings were further bolstered by the recent announcement of statistically significant and robust efficacy data for BIV-201 in patients with refractory ascites. Both clinical candidates are in the advanced clinical phase and have the potential to address significant unmet needs in their respective therapeutic areas. In its BioVie Day presentation, the company explained in detail the historical clinical findings, current progress of the clinical pipeline, and future course of action. Aside from these, the company reaffirmed its confidence in NE3107’s potent dual mechanism of action (MoA) and emphasized a U.S. market potential exceeding $30 billion for NE3107. This article highlights the additional clinical findings from the PD trial and ascites trial, updates on the AD/mild cognitive impairment (MCI) clinical trial, and additional updates from the company’s BioVie Day presentation.
Quantum Research Group, LLC is a New York City-based sponsored equity research and distribution company.
The company focuses on emerging growth public companies that are seeking detailed equity analysis and extensive distribution aimed at the investment community.
Our distribution partners include dozens of the leading financial platforms, including Thomson Reuters, Standard & Poor's Capital IQ, Bloomberg, Zacks, NASDAQ, Yahoo! Finance, and NYSE Connect.
Our reports reach over 20 channels, with our top five platforms reaching over 818,000 readers from both the buy-side and sell-side.
Quantum has a strong proven track record in the fields of Biotechnology/Pharma, Technology, Telecommunication, Media/News, Transportation, Insurance and Fintech.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.